Published on : Apr 07, 2016
ALBANY, New York, April 07, 2016: The global Parkinson’s disease (PD) therapeutics market was valued at US$16.1 mn in 2011 and is expected to expand rapidly in the years to come. Parkinson’s disease (PD) is a chronic, progressive neurodegenerative condition, which is at present incurable. PD is primarily associated with old age and is marked by the loss of neurons in the substantia nigra area of the brain. After Alzheimer’s disease, PD is the second most common neurodegenerative disease globally. Although PD is not deadly, it can develop many severe symptoms and bodily complications that directly impact the patient’s quality of living. Parkinson’s disease has symptoms for each stage, which are categorized into early stage, moderate, and advanced stage. Difficulty in walking and tremors are two of the most common motor symptoms of Parkinson’s disease.
PD also gives rise to some non-motor symptoms including depression, dementia, loss of smell and taste, and hallucinations. PD is treated by many different drugs and treatments. Some of the therapies commonly practiced to treat PD are levodopa, monoamine oxidase-B (MAO-B) inhibitors, dopamine agonists, and others. The choice of treatments and therapies depends on the lifestyle and symptoms of the patients. As PD develops in the advanced stage, a strict medication regime is required. Currently, leading players in the global Parkinson's disease (PD) therapeutics market are focusing on manufacturing medicines that give symptomatic relief.
Click here to get more info with TOC in a PDF Format: http://www.researchmoz.us/enquiry.php?type=S&repid=668356
At present, even though PD remains incurable, leading players are expected to come up with certain treatments and medicines that could minimize the ill effects of PD on the human body. Due to the absence of clearly defined and established clinical trial methods, replication of the benefits that are demonstrated by neuroprotective agents in laboratories has proved to be challenging. Moreover, due to incomplete understanding of the underlying mechanisms causing PD, a feasible therapeutic target to slow down or halt the development of the disease is currently not in the scope of the industry. This is expected to limit the effectiveness of current programs of product development.
The global Parkinson's disease (PD) therapeutics market is divided by geography into North America, Europe, and Japan. Many leading players are expected to sign co-development deals to contribute towards the global Parkinson's disease (PD) therapeutics market. TechnoPhage is predicted to enter into a co-development agreement with the University of Macau. Dainippon Sumitomo Pharma is planning to sign a research agreement with Hitachi and CiRA. Genentech is anticipated to partner with 23andMe, whereas Ubiquigent is predicted to enter into a co-development agreement with UbiQ. Such partnerships, agreements, and mergers are predicted to propel the global Parkinson's disease (PD) therapeutics market in the years to come.
To order report Call USA – Canada Toll Free: 866-997-4948 or send an email on email@example.com